NASDAQ: MNPR
Monopar Therapeutics Stock Ownership - Who owns Monopar Therapeutics?

Insider buying vs selling

Have Monopar Therapeutics insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Andrew CittadineChief Operating Officer2025-12-311,889$65.30
$123.35kSell
Chandler RobinsonChief Executive Officer2025-12-312,558$65.30
$167.04kSell
Quan Anh VuChief Financial Officer2025-12-261,500$69.95
$104.93kBuy
Arthur J. KlausnerDirector2025-12-184,660$67.06
$312.50kSell
Arthur J. KlausnerDirector2025-12-18461$68.09
$31.39kSell
Andrew CittadineChief Operating Officer2025-09-301,896$81.67
$154.85kSell
Chandler RobinsonChief Executive Officer2025-09-302,646$81.67
$216.10kSell
Tactic Pharma LLCChief Executive Officer2025-09-24550,229$63.61
$35.00MSell
Chandler RobinsonChief Executive Officer2025-07-1416,800$40.00
$672.02kSell
Chandler RobinsonChief Executive Officer2025-07-1416,800$0.01
$84.00Buy

1 of 2

MNPR insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when MNPR insiders and whales buy or sell their stock.

MNPR Shareholders

What type of owners hold Monopar Therapeutics stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Arthur J. Klausner137.30%9,174,944$553.98MInsider
Michael J. 1. Brown71.91%4,805,470$290.15MInsider
Tactic Pharma LLC65.59%4,383,299$264.66MInsider
Janus Henderson Group PLC19.26%1,287,368$77.73MInstitution
Adage Capital Partners GP LLC9.86%659,195$39.80MInstitution
Ra Capital Management LP7.65%511,207$30.87MInstitution
Chandler Robinson5.35%357,744$21.60MInsider
Wellington Management Group LLP3.46%231,463$13.98MInstitution
Vanguard Group Inc3.12%208,218$12.57MInstitution
Blackrock Inc3.05%203,751$12.30MInstitution

1 of 3

MNPR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
MNPR18.40%81.60%Net SellingNet Selling
IVVD61.79%38.21%Net SellingNet Buying
VSTM54.51%45.49%Net SellingNet Selling
ASMB50.56%49.44%Net Selling
IMMP0.14%0.00%

Monopar Therapeutics Stock Ownership FAQ

Who owns Monopar Therapeutics?

Monopar Therapeutics (NASDAQ: MNPR) is owned by 64.89% institutional shareholders, 287.67% Monopar Therapeutics insiders, and 0.00% retail investors. Arthur J. Klausner is the largest individual Monopar Therapeutics shareholder, owning 9.17M shares representing 137.30% of the company. Arthur J. Klausner's Monopar Therapeutics shares are currently valued at $553.98M.

If you're new to stock investing, here's how to buy Monopar Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.